Joseph Lutaakome
ID: UNCST-2020-R008323
|
A Multicenter, Adaptive, Randomized, Blinded Controlled Trial of the Safety and Efficacy of Investigational Therapeutics for Hospitalized Patients with COVID-19
REFNo: HS1099ES
SARS-CoV-2 is a novel coronavirus causing COVID-19 and has spread very rapidly. Safe and effective treatments are urgently needed. One antiviral treatment, remdesivir, and an anti-inflammatory drug, dexamethasone, have shown benefit; these are now the COVID-19 standard-of-care treatment for in patients in many parts of the world. The structure of the natural antibodies that hasten recovery from COVID-19 are now known; this means synthetic forms have been manufactured. These synthetic neutralising monoclonal antibodies (nMAb) ‘neutralise’ the virus by binding to it and prevent it from entering cells in the body, including the lungs. By giving an infusion of these nMAb(s) in addition to COVID-19 standard-of-care treatment, we hope hospitalised patients will recover more quickly.
The primary endpoint of TICO is to test whether in hospitalized adults with confirmed COVID-19 infection, the nMAb(s) result in more people with ‘sustained’ recovery i.e. discharged from hospital, alive, and home for 14 consecutive days by Day 90.
1) For everyone enrolled during stage 1 and 2 of the trial the secondary research questions are to define, the numbers of deaths through 90 days of follow-up; the number of people who experience sustained recovery over 90 days, the time to discharge from the initial hospital, and the number of days alive up to day 90.
2) Changes in the scores to assess people’s lung and respiratory function on Days 1-7, and Days 14 and 28.
3) Changes between Day 0 and Day 5 in the National Early Warning (NEW) score, this is a scoring system validated in the UK, which is able to score how sick people are, and their risk of dying, based on things like their blood pressure, pulse rate and body temperature.
4) Clinical organ failure defined by development of any one or more of the following through Day 28
a. Respiratory system dysfunction including the need for oxygen therapy or ventilation
b. Cardiac problems include heart attacks and heart failure
c. Low blood pressure requiring drug support to maintain it
d. kidney dysfunction including needing dialysis
e. liver dysfunction including liver failure and abnormal liver tests
f. Brain and nerve problems including acute confusion, strokes, brain swelling, meningitis, and weakness of the legs
g. Blood problems including major bleeding
h. thrombotic events in the veins or arteries
i. Serious infections including sepsis.
5) Safety and tolerability as measured by: grade 3 and 4 clinical adverse events, serious adverse events, or death through Day 5 and through Day 28; Infusion-related reactions of any severity and the percentage of participants for whom the infusion was interrupted or stopped prior to completion.
6) Change in the levels and types of antibodies against COVID-19, from baseline to Days 1, 3, 5 and 28 and 90.
|
Uganda |
2020-12-18 |
2023-12-18 |
Medical and Health Sciences |
|
Non-degree Award |
|
Patrick Wakida
ID:
|
MARKET RESEARCH STUDY TO UNDERSTAND THE MARKET POTENTIAL FOR CANCER TESTING EQUIPMENT IN UGANDA
REFNo: SS679ES
i. To understand current diagnostic and treatment pathways in breast cancer.
ii. To gain an understanding of breast cancer management including mapping diagnostic and treatment pathways
iii. To understand the processes and challenges of penetrating the invitro diagnostics products market the Uganda.
iv. To determine the need for molecular invitro diagnostics product In Uganda
|
Uganda |
2020-12-18 |
2023-12-18 |
Social Science and Humanities |
|
Non-degree Award |
|
Nelson Sewankambo K
ID: UNCST-2020-R014578
|
Feasibility and acceptability of Dialog+ in Primary care-Uganda
REFNo: HS1116ES
i. test the feasibility and acceptability of DIALOG+ for patients with non-communicable physical health conditions in primary care
ii. explore the adaption of Dialog+ intervention through a process of stakeholder consultation and refine the training materials to promote wider implementation and upscale
iii. explore the effect of using the adapted Dialog+ intervention on patient outcomes
|
Uganda |
2020-12-18 |
2023-12-18 |
Medical and Health Sciences |
|
Non-degree Award |
|
Catherine Mwesigwa
ID: UNCST-2019-R000988
|
FEASIBILITY OF INTEGRATING ORAL HEALTH IN THE PRIMARY CARE OF HIV PEDIATRIC PATIENTS IN KAMPALA, UGANDA
REFNo: HS1055ES
1. To determine the factors that influence integrating oral health at pediatric HIV care facilities.
2. To assess the effectiveness of an oral health education intervention in pediatric HIV care.
3. To explore the feasibility of integrating oral health within primary HIV-care in a low-resource setting
|
Uganda |
2020-12-17 |
2023-12-17 |
Medical and Health Sciences |
|
Non-degree Award |
|
Nazarius Tumwesigye Mbona
ID: UNCST-2019-R000664
|
Research Protocol for the Impact and Economic Evaluation of Health Systems Strengthening Interventions in the West Nile region of Uganda
REFNo: HS1110ES
To determine the status and associated factors (i. DHSS intervention, ii. Quality of Care, iii. SBCC) of coverage of maternal and child health and nutrition services in intervention and counterfactual districts during 2019
2: To determine the status and associated factors (i. DHSS intervention, ii. Quality of Care, iii. SBCC) of use of maternal and child health and nutrition services in intervention and counterfactual districts during 2019
3: To determine the differences and the associated factors (i. DHSS intervention, ii. Quality of Care, iii. SBCC) of the change in coverage of maternal and child health and nutrition services from 2019 to 2024 between intervention and counterfactual districts
4: To determine the differences and the associated factors (i. DHSS intervention, ii. Quality of Care, iii. SBCC) of the change in use of maternal and child health and nutrition services from 2019 to 2024 between intervention and counterfactual districts
5: To establish the cost and effectiveness of DHSS, quality improvement and SBCC in the use and coverage of maternal and child health and nutrition services from 2019-2024
|
Uganda |
2020-12-17 |
2023-12-17 |
Medical and Health Sciences |
|
Non-degree Award |
|
| View |
|
Sort By: |
|
|
|
| |
|